Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for Suicidal Ideation in OUD
NCT04234516Phase 4Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of buprenorphine in opioid use disorder (OUD), suicidal ideation, sponsored by New York State Psychiatric Institute. Planned start Jan 2020; status: withdrawn.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)suicidal ideation
Beyond the preview
Go deeper on NCT04234516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234516.